文献速递肝病

RIPK3作为脂代谢调节因子促进非酒精性脂肪性肝病的炎症和癌变

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
PubMed 文献 · Gut · 2020-12-24

该研究在两个人NAFLD队列中评估RIPK3水平,并用野生型或Ripk3缺陷小鼠喂食CDAA或对照饮食32和66周。结果显示NASH患者肝RIPK3升高且与炎症和纤维化相关,Ripk3缺陷改善小鼠炎症、纤维化、癌前结节和肿瘤发生,并改变肝脏脂质谱和增加PPARγ。结论提示靶向RIPK3是治疗NASH的新策略。

要点

  • NASH患者肝RIPK3升高,与肝脏炎症和纤维化相关。
  • Ripk3缺陷改善CDAA饮食小鼠的炎症、纤维化及肿瘤发生。
  • RIPK3通过PPARγ调控肝脏脂质沉积和纤维化。

核心结论

  • 肝RIPK3在人类和小鼠中与NAFLD严重程度相关,在管理肝脏代谢、损伤、炎症、纤维化和癌变中起关键作用。
  • 靶向RIPK3及其信号网络是治疗NASH和阻止疾病进展的新兴有前景的方法。

研究设计与样本

  • 在两个人NAFLD活检诊断的独立队列中评估RIPK3水平,并与临床和生化参数相关。
  • 野生型或Ripk3缺陷小鼠喂食CDAA饮食或等热量对照饮食32和66周。

主要发现

  • 两个队列中NASH患者RIPK3升高,与肝脏炎症和纤维化相关。
  • Ripk3缺陷在32和66周均改善CDAA诱导的小鼠炎症和纤维化。
  • WT小鼠CDAA饮食66周出现癌前结节和肝细胞增殖增加,Ripk3-/-小鼠中减少。
  • Ripk3缺陷阻碍肿瘤发生,Ripk3-/-小鼠体重增加增加,脂质组学显示肝脏脂质谱改变。
  • Ripk3-/-小鼠PPARγ增加,且与NAFLD患者肝RIPK3负相关;机制研究建立RIPK3与PPARγ控制脂肪沉积和纤维化的功能联系。

临床怎么用

  • 肝RIPK3水平可能作为NAFLD严重程度的生物标志物。
  • 靶向RIPK3信号可能成为治疗NASH和阻止疾病进展的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD. DESIGN: RIPK3 levels were evaluated in two large independent cohorts of patients with biopsy proven NAFLD diagnosis and correlated with clinical and biochemical parameters. Wild-type (WT) or Ripk3-deficient (Ripk3-/-) mice were fed a choline-deficient L-amino acid-defined diet (CDAA) or an isocaloric control diet for 32 and 66 weeks. RESULTS: RIPK3 increased in patients with non-alcoholic steatohepatitis (NASH) in both cohorts, correlating with hepatic inflammation and fibrosis. Accordingly, Ripk3 deficiency ameliorated CDAA-induced inflammation and fibrosis in mice at both 32 and 66 weeks. WT mice on the CDAA diet for 66 weeks developed preneoplastic nodules and displayed increased hepatocellular proliferation, which were reduced in Ripk3-/- mice. Furthermore, Ripk3 deficiency hampered tumourigenesis. Intriguingly, Ripk3-/- mice displayed increased body weight gain, while lipidomics showed that deletion of Ripk3 shifted hepatic lipid profiles. Peroxisome proliferator-activated receptor γ (PPARγ) was increased in Ripk3-/- mice and negatively correlated with hepatic RIPK3 in patients with NAFLD. Mechanistic studies established a functional link between RIPK3 and PPARγ in controlling fat deposition and fibrosis. CONCLUSION: Hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. Targeting RIPK3 and its intricate signalling arises as a novel promising approach to treat NASH and arrest disease progression.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Afonso MB, Rodrigues PM, Mateus-Pinheiro M, et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut. 2020. PMID: 33361348. doi:10.1136/gutjnl-2020-321767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。